seed
Stage
About
EvlaBio develops a selective monoclonal antibody targeting FGFR4 to treat left ventricular hypertrophy in patients with chronic kidney disease by blocking pathological cardiac remodeling caused by aberrant FGF23-FGFR4 signaling.
Explore EvlaBio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.